ENDRA Life Sciences reports FY2025 net loss $7.0M; initiates strategic alternatives review

ENDRA Life Sciences Inc.

Net loss for Q4 2025 $3.2M vs $4.2M YoY; full year net loss $7.0M vs $11.5M in 2024.
Operating expenses fell to $5.8M in 2025 from $10.8M in 2024.
Cash and cash equivalents $762k as of Dec 31, 2025; $2.0M in digital asset treasury.
Board initiated evaluation of strategic alternatives on March 25, 2026; no timetable set.
TAEUS Liver feasibility study showed r=0.89 correlation with MRI-PDFF for liver fat.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ENDRA Life Sciences Inc. reported the quarter and year ended December 31, 2025 results: net income net loss of $3.2 million.

Period: the quarter and year ended December 31, 2025
Net income: net loss of $3.2 million
Result: reported results

Exact text from the filing

in the fourth quarter of 2025 decreased to $1.6 million, compared with $4.3 million in the same period last year. As a result, the net loss in the fourth quarter of 2025 was $3.2 million, compared with a net loss of $4.2 million in the fourth quarter of 2024. 2025 Financial Results During 2025 the Company benefitted from actions taken throughout 2024 to

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

ENDRA Life Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-037497

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.